Trevi Therapeutics Gears Up for August Conference Participation
Trevi Therapeutics, Inc. (NASDAQ: TRVI), a pioneering biopharmaceutical company, is set to make a significant impact at several upcoming conferences, showcasing its innovative approach to addressing chronic cough through its investigational therapy, Haduvio™. This exciting development comes as the company continues to focus on the treatment for patients suffering from chronic cough conditions, particularly those with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC).
Upcoming Conferences
Oppenheimer's Biotech in the Berkshires
From August 4 to 6, 2025, Trevi will be represented at the prestigious Oppenheimer's 2025 Biotech in the Berkshires event. Jennifer Good, the company's President and CEO, will lead the participation, highlighting Trevi's advancements in clinical-stage biopharmaceuticals.
Stifel's Biotech Summer Summit
Shortly after, on August 11 to 13, 2025, Trevi will attend the Stifel's 2025 Biotech Summer Summit. This event is significant, featuring a fireside chat on August 11 at 1:00 p.m. ET, where Jennifer Good, alongside Farrell Simon, Pharm.D., the Chief Commercial Officer, will discuss Trevi's progress and future direction in an open forum.
About Trevi Therapeutics
Trevi Therapeutics is committed to developing Haduvio™, which is undergoing clinical evaluation for chronic cough related to IPF and other challenging conditions. Notably, Haduvio is the first investigational therapy to demonstrate a statistically significant reduction in cough frequency in clinical trials. This therapy targets opioid receptors, serving as both a kappa agonist and mu antagonist (KAMA), effectively acting on the cough reflex arc to alleviate symptoms.
An estimated 85% of patients with IPF experience chronic cough, affecting around 150,000 individuals in the U.S. The persistent nature of this cough can disrupt daily life, causing serious complications and diminishing quality of life. Furthermore, the absence of approved therapies specifically for chronic cough in IPF patients highlights the urgent need for innovative solutions.
The Challenge of Refractory Chronic Cough
Refractory chronic cough remains a challenging condition, with approximately 2-3 million individuals in the United States affected. This type of cough lasts more than eight weeks and requires careful management as it may stem from various underlying diseases. The incessant nature of this cough can lead to significant psychological and social challenges, markedly increasing the burden on patients and their families.
Trevi’s focus on creating effective solutions for chronic cough showcases its dedication to improving patient outcomes. By proposing the trade name Haduvio for oral nalbuphine ER, Trevi is paving the way for a potential breakthrough in treatment, though it is essential to note that safety and efficacy assessments remain pending regulatory authority evaluations.
Staying Connected
Patients, investors, and interested parties can learn more about Trevi Therapeutics and its groundbreaking work in chronic cough solutions by visiting its official website and social media platforms. Stay informed about the latest updates by following Trevi on social media, including X (formerly Twitter) and LinkedIn.
Contact Information
For investors seeking more information or having inquiries about Trevi, Jonathan Carlson can be reached directly at Trevi Therapeutics, Inc. at (203) 654 3286.
Media inquiries can be directed to Rosalia Scampoli at 914-815-1465 for further details on Trevi's upcoming initiatives.
Frequently Asked Questions
What is Trevi Therapeutics focusing on?
Trevi Therapeutics is dedicated to developing treatments for chronic cough in patients, specifically through its investigational therapy, Haduvio™.
Who will represent Trevi Therapeutics at the conferences?
Jennifer Good, President and CEO, will be representing Trevi at the Oppenheimer conference, along with other key representatives at different events.
What conditions is Haduvio™ targeting?
Haduvio™ aims to treat chronic cough associated with idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough.
Why is chronic cough a significant concern for patients?
Chronic cough significantly impacts daily life, causing complications and emotional distress due to its persistent nature, affecting up to 85% of IPF patients.
How can I get more information about Trevi Therapeutics?
Visit Trevi Therapeutics' official website or follow them on social media platforms like X (formerly Twitter) and LinkedIn for updates and further details.
